-
Something wrong with this record ?
Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer
VM. Schuettfort, B. Pradere, QD. Trinh, D. D'Andrea, F. Quhal, H. Mostafaei, E. Laukhtina, K. Mori, R. Sari Motlagh, M. Rink, PI. Karakiewicz, P. Chlosta, J. Yuen-Chun Teoh, Y. Lotan, D. Scherr, M. Abufaraj, M. Moschini, SF. Shariat
Language English Country Germany
Document type Journal Article
NLK
PubMed Central
from 1982
ProQuest Central
from 1997-03-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2000-04-01 to 1 year ago
Health & Medicine (ProQuest)
from 1997-03-01 to 1 year ago
Public Health Database (ProQuest)
from 1997-03-01 to 1 year ago
- MeSH
- Biomarkers metabolism MeSH
- Cystectomy methods MeSH
- Interleukin-6 blood MeSH
- Kaplan-Meier Estimate MeSH
- Middle Aged MeSH
- Humans MeSH
- Lymphatic Metastasis MeSH
- Multivariate Analysis MeSH
- Urinary Bladder Neoplasms blood surgery MeSH
- Postoperative Period MeSH
- Preoperative Period MeSH
- Proportional Hazards Models MeSH
- Prospective Studies MeSH
- Receptors, Interleukin-6 blood MeSH
- Regression Analysis MeSH
- Decision Making MeSH
- Aged MeSH
- Decision Support Systems, Clinical MeSH
- Urothelium pathology surgery MeSH
- Treatment Outcome MeSH
- Inflammation MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: Preoperative plasma levels of Interleukin 6 (IL6) and its soluble receptor (IL6sR) have previously been associated with oncologic outcomes in urothelial carcinoma of the bladder (UCB); however, external validation in patients treated with radical cystectomy (RC) for UCB is missing. PATIENTS/METHODS: We prospectively collected preoperative plasma from 1,036 consecutive patients at two institutes. These plasma specimens were assessed for levels of IL6 and IL6sR. Logistic and Cox regression analyses were used to assess the correlation of plasma levels with pathologic and survival outcomes. The additional clinical net benefits of preoperative IL6 and IL6sR were evaluated using decision curve analysis (DCA). RESULTS: Median IL6 and IL6sR plasma levels were significantly higher in patients with adverse pathologic features. Elevated biomarker levels were independently associated with an increased risk for lymph node metastasis and ≥ pT3 disease. Both biomarkers were independently associated with recurrence-free survival (RFS), cancer-specific survival (CSS) and overall survival (OS). The addition to, respectively, fitted pre- and postoperative prognostic models improved the predictive accuracy for lymph node metastasis, ≥ pT3 disease, RFS and CSS on DCA. INTERPRETATION: We confirmed that elevated preoperative plasma levels of IL6 and IL6sR levels are associated with worse oncological disease survival in patients treated with RC for UCB in a large multicenter study. Both biomarkers hold potential in identifying patients with adverse pathological features that may benefit from intensified/multimodal therapy and warrant inclusion into predictive/prognostic models. They demonstrated the ability to improve the discriminatory power of such models and thus guide clinical decision making.
Department of Urology Hospital Motol 2nd Faculty of Medicine Charles University Praha Czech Republic
Department of Urology Institut Mutualiste Montsouris Paris France
Department of Urology King Fahad Specialist Hospital Dammam Saudi Arabia
Department of Urology Luzerner Kantonsspital Lucerne Switzerland
Department of Urology Medical College Jagiellonian University Krakow Poland
Department of Urology The Jikei University School of Medicine Tokyo Japan
Department of Urology University Medical Center Hamburg Eppendorf Hamburg Germany
Department of Urology University of Texas Southwestern Dallas TX USA
Department of Urology Weill Cornell Medical College New York Presbyterian Hospital New York USA
European Association of Urology Research Foundation Arnhem Netherlands
Institute for Urology and Reproductive Health Sechenov University Moscow Russia
Karl Landsteiner Institute of Urology and Andrology Vienna Austria
Research Center for Evidence Based Medicine Tabriz University of Medical Sciences Tabriz Iran
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22011434
- 003
- CZ-PrNML
- 005
- 20220506125828.0
- 007
- ta
- 008
- 220425s2022 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00262-021-02953-0 $2 doi
- 035 __
- $a (PubMed)34023914
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Schuettfort, Victor M $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany $1 https://orcid.org/0000000271140508
- 245 10
- $a Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer / $c VM. Schuettfort, B. Pradere, QD. Trinh, D. D'Andrea, F. Quhal, H. Mostafaei, E. Laukhtina, K. Mori, R. Sari Motlagh, M. Rink, PI. Karakiewicz, P. Chlosta, J. Yuen-Chun Teoh, Y. Lotan, D. Scherr, M. Abufaraj, M. Moschini, SF. Shariat
- 520 9_
- $a BACKGROUND: Preoperative plasma levels of Interleukin 6 (IL6) and its soluble receptor (IL6sR) have previously been associated with oncologic outcomes in urothelial carcinoma of the bladder (UCB); however, external validation in patients treated with radical cystectomy (RC) for UCB is missing. PATIENTS/METHODS: We prospectively collected preoperative plasma from 1,036 consecutive patients at two institutes. These plasma specimens were assessed for levels of IL6 and IL6sR. Logistic and Cox regression analyses were used to assess the correlation of plasma levels with pathologic and survival outcomes. The additional clinical net benefits of preoperative IL6 and IL6sR were evaluated using decision curve analysis (DCA). RESULTS: Median IL6 and IL6sR plasma levels were significantly higher in patients with adverse pathologic features. Elevated biomarker levels were independently associated with an increased risk for lymph node metastasis and ≥ pT3 disease. Both biomarkers were independently associated with recurrence-free survival (RFS), cancer-specific survival (CSS) and overall survival (OS). The addition to, respectively, fitted pre- and postoperative prognostic models improved the predictive accuracy for lymph node metastasis, ≥ pT3 disease, RFS and CSS on DCA. INTERPRETATION: We confirmed that elevated preoperative plasma levels of IL6 and IL6sR levels are associated with worse oncological disease survival in patients treated with RC for UCB in a large multicenter study. Both biomarkers hold potential in identifying patients with adverse pathological features that may benefit from intensified/multimodal therapy and warrant inclusion into predictive/prognostic models. They demonstrated the ability to improve the discriminatory power of such models and thus guide clinical decision making.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a biologické markery $x metabolismus $7 D015415
- 650 _2
- $a cystektomie $x metody $7 D015653
- 650 _2
- $a rozhodování $7 D003657
- 650 _2
- $a systémy pro podporu klinického rozhodování $7 D020000
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a zánět $7 D007249
- 650 _2
- $a interleukin-6 $x krev $7 D015850
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a lymfatické metastázy $7 D008207
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a multivariační analýza $7 D015999
- 650 _2
- $a pooperační období $7 D011184
- 650 _2
- $a předoperační období $7 D057234
- 650 _2
- $a proporcionální rizikové modely $7 D016016
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a receptory interleukinu-6 $x krev $7 D019947
- 650 _2
- $a regresní analýza $7 D012044
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a nádory močového měchýře $x krev $x chirurgie $7 D001749
- 650 _2
- $a urotel $x patologie $x chirurgie $7 D019459
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
- 700 1_
- $a Trinh, Quoc-Dien $u Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- 700 1_
- $a D'Andrea, David $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
- 700 1_
- $a Quhal, Fahad $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia
- 700 1_
- $a Mostafaei, Hadi $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
- 700 1_
- $a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
- 700 1_
- $a Mori, Keiichiro $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
- 700 1_
- $a Sari Motlagh, Reza $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
- 700 1_
- $a Rink, Michael $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- 700 1_
- $a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada
- 700 1_
- $a Chlosta, Piotr $u Department of Urology, Medical College, Jagiellonian University, Krakow, Poland
- 700 1_
- $a Yuen-Chun Teoh, Jeremy $u S.H. Ho Urology Centre, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China
- 700 1_
- $a Lotan, Yair $u Department of Urology, University of Texas Southwestern, Dallas, TX, USA
- 700 1_
- $a Scherr, Douglas $u Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, USA
- 700 1_
- $a Abufaraj, Mohammad $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan
- 700 1_
- $a Moschini, Marco $u Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland $u Department of Urology, Institut Mutualiste Montsouris, Paris, France $u Department of Urology and Division of Experimental Oncology, Urological Research Institute, Vita-Salute San Raffaele, Milan, Italy
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, University of Texas Southwestern, Dallas, TX, USA. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, USA. shahrokh.shariat@meduniwien.ac.at $u Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Praha, Czech Republic. shahrokh.shariat@meduniwien.ac.at $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at $u European Association of Urology Research Foundation, Arnhem, Netherlands. shahrokh.shariat@meduniwien.ac.at
- 773 0_
- $w MED00001041 $t Cancer immunology, immunotherapy : CII $x 1432-0851 $g Roč. 71, č. 1 (2022), s. 85-95
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34023914 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506125821 $b ABA008
- 999 __
- $a ok $b bmc $g 1789165 $s 1162632
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 71 $c 1 $d 85-95 $e 20210523 $i 1432-0851 $m Cancer immunology and immunotherapy $n Cancer Immunol Immunother $x MED00001041
- LZP __
- $a Pubmed-20220425
